Julana Schenk, MD
Psychiatry · Layton, UTNPI 1457321556
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 25.8% of the total. Reporting peaked in 2021 at $411 and has fallen 93.1% since, to $29 in 2025.
Across 69 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$291
- AbbVie$290
- Johnson & Johnson$162
- Otsuka America Pharmaceutical, Inc.$128
- Indivior Inc.$81
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$64
- plus $108 from 4 others
What the payments were for
- Food & beverage$1,07896%
- Education$474%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 19 | $291 |
| AbbVie(2 entities) | 22 | $290 |
| Johnson & Johnson | 8 | $162 |
| Otsuka America Pharmaceutical, Inc. | 8 | $128 |
| Indivior Inc. | 4 | $81 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $64 |
| Vanda Pharmaceuticals Inc. | 3 | $45 |
| Neuronetics, Inc. | 1 | $29 |
| Alkermes, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$1,125 in reported general payments places this provider in the 85th percentile of 231 psychiatry providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 128 | $324,078 |
| Abilify MaintenaAripiprazole | 57 | $154,485 |
| VivitrolNaltrexone Microspheres | 56 | $90,022 |
| LybalviOlanzapine/Samidorphan Malate | 27 | $59,016 |
| Zyprexa RelprevvOlanzapine Pamoate | 38 | $52,050 |
| SublocadeBuprenorphine | 22 | $43,169 |
| VraylarCariprazine Hcl | 25 | $33,621 |
| AristadaAripiprazole Lauroxil | 12 | $32,891 |
| CaplytaLumateperone Tosylate | 19 | $30,053 |
| Risperdal ConstaRisperidone Microspheres | 13 | $29,912 |
| ClozarilClozapine | 24 | $20,533 |
| Clozapine | 369 | $20,139 |
| BrixadiBuprenorphine | 11 | $19,014 |
| Paliperidone ErPaliperidone | 60 | $16,722 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 63 | $16,168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $162 | $353,990141 claims |
| Alkermes, Inc.Vivitrol, Lybalvi, Aristada | $22 | $181,93095 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $128 | $154,48557 claims |
| AbbVieVraylar, Linzess | $290 | $47,34052 claims |
| Indivior Inc.Sublocade | $81 | $43,16922 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $64 | $30,05319 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $13 | $12,90327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 231 psychiatry providers in Utah.
Other psychiatry in Layton
- Benjamin van LeeuwenLayton$6K
- Julie WieseLayton$4K
- Anthony VitaLayton$823
- Michael MeasomSlc$2.2M
- Noel GardnerSalt Lake City$512K
- Reid RobisonOrem$133K
- Thomas RaynerProvo$60K
- Trent HolmbergDraper$32K
- Nathan CurrierRiverton$21K
- Oliver McPhersonBountiful$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.